Amphetamine-induced striatal dopamine release in schizotypal personality disorder
Rationale Previous research has suggested that schizotypal personality disorder (SPD), a condition that shares clinical and cognitive features with schizophrenia, may be associated with elevated striatal dopamine functioning; however, there are no published studies of dopamine release within subregi...
Gespeichert in:
Veröffentlicht in: | Psychopharmacology 2020-09, Vol.237 (9), p.2649-2659 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2659 |
---|---|
container_issue | 9 |
container_start_page | 2649 |
container_title | Psychopharmacology |
container_volume | 237 |
creator | Thompson, Judy L. Rosell, Daniel R. Slifstein, Mark Xu, Xiaoyan Rothstein, Ethan G. Modiano, Yosefa A. Kegeles, Lawrence S. Koenigsberg, Harold W. New, Antonia S. Hazlett, Erin A. McClure, Margaret M. Perez-Rodriguez, M. Mercedes Siever, Larry J. Abi-Dargham, Anissa |
description | Rationale
Previous research has suggested that schizotypal personality disorder (SPD), a condition that shares clinical and cognitive features with schizophrenia, may be associated with elevated striatal dopamine functioning; however, there are no published studies of dopamine release within subregions of the striatum in SPD.
Objectives
To characterize dopamine release capacity in striatal subregions and its relation to clinical and cognitive features in SPD.
Methods
We used positron emission tomography with [
11
C]raclopride and an amphetamine challenge to measure dopamine D2-receptor availability (binding potential, BP
ND
), and its percent change post-amphetamine (∆BP
ND
) to index amphetamine-induced dopamine release, in subregions of the striatum in 16 SPD and 16 healthy control participants. SPD participants were evaluated with measures of schizotypal symptom severity and working memory.
Results
There were no significant group differences in BP
ND
or ∆BP
ND
in any striatal subregion or whole striatum. Among SPD participants, cognitive-perceptual symptoms were associated at trend level with ∆BP
ND
in the ventral striatum, and disorganized symptoms were significantly negatively related to ∆BP
ND
in several striatal subregions.
Conclusions
In contrast to previous findings, SPD was not associated with elevated striatal dopamine release. However, in SPD, there was a moderate positive association between ventral striatal dopamine release and severity of cognitive-perceptual symptoms, and negative associations between striatal dopamine release and severity of disorganized symptoms. Future larger scale investigations that allow for the separate examination of subgroups of participants based on clinical presentation will be valuable in further elucidating striatal DA functioning in SPD. |
doi_str_mv | 10.1007/s00213-020-05561-5 |
format | Article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2416272826</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A635911686</galeid><sourcerecordid>A635911686</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-3944c37bcc633b8176c1e655ae5a2e75ab7b6bb80e18449e2c102026176fce943</originalsourceid><addsrcrecordid>eNp9kU9L5TAUxYOM6Bv1C7iQghs30fxvunyIOgOCCLoOaXqrkbapSbt48-kn7z1HUWSSRSD3dw73cBA6puScElJeJEIY5ZgwgomUimK5gxZUcIYZKdkPtCCEc8yp1PvoZ0ovJB-hxR7a50yWTGq9QPfLfnyGyfZ-AOyHZnbQFGmK3k62K5owbiZFhA5sgsIPRXLP_k-YVmOejxBTGGznp1XR-BRiA_EQ7ba2S3D09h6gx-urh8tf-Pbu5vfl8hY7IdiEeSWE42XtnOK81rRUjoKS0oK0DEpp67JWda0JUC1EBczRHJSpDLYOKsEP0NnWd4zhdYY0md4nB11nBwhzMkxQxUqmmcro6Rf0Jcwx750pqYSqNFfig3qyHRg_tGGK1q1NzVJxWVGq9Nrr_Bsq3wZ678IArc__nwRsK3AxpBShNWP0vY0rQ4lZ92i2PZocz2x6NDKLTt42nusemnfJv-IywLdAyqPhCeJHpP_Y_gWUwKZs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2564698364</pqid></control><display><type>article</type><title>Amphetamine-induced striatal dopamine release in schizotypal personality disorder</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Thompson, Judy L. ; Rosell, Daniel R. ; Slifstein, Mark ; Xu, Xiaoyan ; Rothstein, Ethan G. ; Modiano, Yosefa A. ; Kegeles, Lawrence S. ; Koenigsberg, Harold W. ; New, Antonia S. ; Hazlett, Erin A. ; McClure, Margaret M. ; Perez-Rodriguez, M. Mercedes ; Siever, Larry J. ; Abi-Dargham, Anissa</creator><creatorcontrib>Thompson, Judy L. ; Rosell, Daniel R. ; Slifstein, Mark ; Xu, Xiaoyan ; Rothstein, Ethan G. ; Modiano, Yosefa A. ; Kegeles, Lawrence S. ; Koenigsberg, Harold W. ; New, Antonia S. ; Hazlett, Erin A. ; McClure, Margaret M. ; Perez-Rodriguez, M. Mercedes ; Siever, Larry J. ; Abi-Dargham, Anissa</creatorcontrib><description>Rationale
Previous research has suggested that schizotypal personality disorder (SPD), a condition that shares clinical and cognitive features with schizophrenia, may be associated with elevated striatal dopamine functioning; however, there are no published studies of dopamine release within subregions of the striatum in SPD.
Objectives
To characterize dopamine release capacity in striatal subregions and its relation to clinical and cognitive features in SPD.
Methods
We used positron emission tomography with [
11
C]raclopride and an amphetamine challenge to measure dopamine D2-receptor availability (binding potential, BP
ND
), and its percent change post-amphetamine (∆BP
ND
) to index amphetamine-induced dopamine release, in subregions of the striatum in 16 SPD and 16 healthy control participants. SPD participants were evaluated with measures of schizotypal symptom severity and working memory.
Results
There were no significant group differences in BP
ND
or ∆BP
ND
in any striatal subregion or whole striatum. Among SPD participants, cognitive-perceptual symptoms were associated at trend level with ∆BP
ND
in the ventral striatum, and disorganized symptoms were significantly negatively related to ∆BP
ND
in several striatal subregions.
Conclusions
In contrast to previous findings, SPD was not associated with elevated striatal dopamine release. However, in SPD, there was a moderate positive association between ventral striatal dopamine release and severity of cognitive-perceptual symptoms, and negative associations between striatal dopamine release and severity of disorganized symptoms. Future larger scale investigations that allow for the separate examination of subgroups of participants based on clinical presentation will be valuable in further elucidating striatal DA functioning in SPD.</description><identifier>ISSN: 0033-3158</identifier><identifier>EISSN: 1432-2072</identifier><identifier>DOI: 10.1007/s00213-020-05561-5</identifier><identifier>PMID: 32572588</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adolescent ; Adult ; Amphetamine - pharmacology ; Amphetamines ; Biomedical and Life Sciences ; Biomedicine ; Brain research ; Cognitive ability ; Corpus Striatum - diagnostic imaging ; Corpus Striatum - drug effects ; Corpus Striatum - metabolism ; Dopamine ; Dopamine - metabolism ; Dopamine D2 receptors ; Dopamine Uptake Inhibitors - pharmacology ; Female ; Humans ; Male ; Medical colleges ; Memory, Short-Term - drug effects ; Memory, Short-Term - physiology ; Mental disorders ; Middle Aged ; Neostriatum ; Neurosciences ; Original Investigation ; Personality ; Personality disorders ; PET imaging ; Pharmacology/Toxicology ; Phenols ; Positron emission tomography ; Positron-Emission Tomography - methods ; Psychiatry ; Raclopride ; Receptors, Dopamine D2 - metabolism ; Schizophrenia ; Schizotypal personality disorder ; Schizotypal Personality Disorder - diagnostic imaging ; Schizotypal Personality Disorder - metabolism ; Schizotypal Personality Disorder - psychology ; Short term memory ; Young Adult</subject><ispartof>Psychopharmacology, 2020-09, Vol.237 (9), p.2649-2659</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020</rights><rights>COPYRIGHT 2020 Springer</rights><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-3944c37bcc633b8176c1e655ae5a2e75ab7b6bb80e18449e2c102026176fce943</citedby><cites>FETCH-LOGICAL-c442t-3944c37bcc633b8176c1e655ae5a2e75ab7b6bb80e18449e2c102026176fce943</cites><orcidid>0000-0001-8964-4934</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00213-020-05561-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00213-020-05561-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32572588$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Thompson, Judy L.</creatorcontrib><creatorcontrib>Rosell, Daniel R.</creatorcontrib><creatorcontrib>Slifstein, Mark</creatorcontrib><creatorcontrib>Xu, Xiaoyan</creatorcontrib><creatorcontrib>Rothstein, Ethan G.</creatorcontrib><creatorcontrib>Modiano, Yosefa A.</creatorcontrib><creatorcontrib>Kegeles, Lawrence S.</creatorcontrib><creatorcontrib>Koenigsberg, Harold W.</creatorcontrib><creatorcontrib>New, Antonia S.</creatorcontrib><creatorcontrib>Hazlett, Erin A.</creatorcontrib><creatorcontrib>McClure, Margaret M.</creatorcontrib><creatorcontrib>Perez-Rodriguez, M. Mercedes</creatorcontrib><creatorcontrib>Siever, Larry J.</creatorcontrib><creatorcontrib>Abi-Dargham, Anissa</creatorcontrib><title>Amphetamine-induced striatal dopamine release in schizotypal personality disorder</title><title>Psychopharmacology</title><addtitle>Psychopharmacology</addtitle><addtitle>Psychopharmacology (Berl)</addtitle><description>Rationale
Previous research has suggested that schizotypal personality disorder (SPD), a condition that shares clinical and cognitive features with schizophrenia, may be associated with elevated striatal dopamine functioning; however, there are no published studies of dopamine release within subregions of the striatum in SPD.
Objectives
To characterize dopamine release capacity in striatal subregions and its relation to clinical and cognitive features in SPD.
Methods
We used positron emission tomography with [
11
C]raclopride and an amphetamine challenge to measure dopamine D2-receptor availability (binding potential, BP
ND
), and its percent change post-amphetamine (∆BP
ND
) to index amphetamine-induced dopamine release, in subregions of the striatum in 16 SPD and 16 healthy control participants. SPD participants were evaluated with measures of schizotypal symptom severity and working memory.
Results
There were no significant group differences in BP
ND
or ∆BP
ND
in any striatal subregion or whole striatum. Among SPD participants, cognitive-perceptual symptoms were associated at trend level with ∆BP
ND
in the ventral striatum, and disorganized symptoms were significantly negatively related to ∆BP
ND
in several striatal subregions.
Conclusions
In contrast to previous findings, SPD was not associated with elevated striatal dopamine release. However, in SPD, there was a moderate positive association between ventral striatal dopamine release and severity of cognitive-perceptual symptoms, and negative associations between striatal dopamine release and severity of disorganized symptoms. Future larger scale investigations that allow for the separate examination of subgroups of participants based on clinical presentation will be valuable in further elucidating striatal DA functioning in SPD.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Amphetamine - pharmacology</subject><subject>Amphetamines</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Brain research</subject><subject>Cognitive ability</subject><subject>Corpus Striatum - diagnostic imaging</subject><subject>Corpus Striatum - drug effects</subject><subject>Corpus Striatum - metabolism</subject><subject>Dopamine</subject><subject>Dopamine - metabolism</subject><subject>Dopamine D2 receptors</subject><subject>Dopamine Uptake Inhibitors - pharmacology</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical colleges</subject><subject>Memory, Short-Term - drug effects</subject><subject>Memory, Short-Term - physiology</subject><subject>Mental disorders</subject><subject>Middle Aged</subject><subject>Neostriatum</subject><subject>Neurosciences</subject><subject>Original Investigation</subject><subject>Personality</subject><subject>Personality disorders</subject><subject>PET imaging</subject><subject>Pharmacology/Toxicology</subject><subject>Phenols</subject><subject>Positron emission tomography</subject><subject>Positron-Emission Tomography - methods</subject><subject>Psychiatry</subject><subject>Raclopride</subject><subject>Receptors, Dopamine D2 - metabolism</subject><subject>Schizophrenia</subject><subject>Schizotypal personality disorder</subject><subject>Schizotypal Personality Disorder - diagnostic imaging</subject><subject>Schizotypal Personality Disorder - metabolism</subject><subject>Schizotypal Personality Disorder - psychology</subject><subject>Short term memory</subject><subject>Young Adult</subject><issn>0033-3158</issn><issn>1432-2072</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kU9L5TAUxYOM6Bv1C7iQghs30fxvunyIOgOCCLoOaXqrkbapSbt48-kn7z1HUWSSRSD3dw73cBA6puScElJeJEIY5ZgwgomUimK5gxZUcIYZKdkPtCCEc8yp1PvoZ0ovJB-hxR7a50yWTGq9QPfLfnyGyfZ-AOyHZnbQFGmK3k62K5owbiZFhA5sgsIPRXLP_k-YVmOejxBTGGznp1XR-BRiA_EQ7ba2S3D09h6gx-urh8tf-Pbu5vfl8hY7IdiEeSWE42XtnOK81rRUjoKS0oK0DEpp67JWda0JUC1EBczRHJSpDLYOKsEP0NnWd4zhdYY0md4nB11nBwhzMkxQxUqmmcro6Rf0Jcwx750pqYSqNFfig3qyHRg_tGGK1q1NzVJxWVGq9Nrr_Bsq3wZ678IArc__nwRsK3AxpBShNWP0vY0rQ4lZ92i2PZocz2x6NDKLTt42nusemnfJv-IywLdAyqPhCeJHpP_Y_gWUwKZs</recordid><startdate>20200901</startdate><enddate>20200901</enddate><creator>Thompson, Judy L.</creator><creator>Rosell, Daniel R.</creator><creator>Slifstein, Mark</creator><creator>Xu, Xiaoyan</creator><creator>Rothstein, Ethan G.</creator><creator>Modiano, Yosefa A.</creator><creator>Kegeles, Lawrence S.</creator><creator>Koenigsberg, Harold W.</creator><creator>New, Antonia S.</creator><creator>Hazlett, Erin A.</creator><creator>McClure, Margaret M.</creator><creator>Perez-Rodriguez, M. Mercedes</creator><creator>Siever, Larry J.</creator><creator>Abi-Dargham, Anissa</creator><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QR</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8964-4934</orcidid></search><sort><creationdate>20200901</creationdate><title>Amphetamine-induced striatal dopamine release in schizotypal personality disorder</title><author>Thompson, Judy L. ; Rosell, Daniel R. ; Slifstein, Mark ; Xu, Xiaoyan ; Rothstein, Ethan G. ; Modiano, Yosefa A. ; Kegeles, Lawrence S. ; Koenigsberg, Harold W. ; New, Antonia S. ; Hazlett, Erin A. ; McClure, Margaret M. ; Perez-Rodriguez, M. Mercedes ; Siever, Larry J. ; Abi-Dargham, Anissa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-3944c37bcc633b8176c1e655ae5a2e75ab7b6bb80e18449e2c102026176fce943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Amphetamine - pharmacology</topic><topic>Amphetamines</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Brain research</topic><topic>Cognitive ability</topic><topic>Corpus Striatum - diagnostic imaging</topic><topic>Corpus Striatum - drug effects</topic><topic>Corpus Striatum - metabolism</topic><topic>Dopamine</topic><topic>Dopamine - metabolism</topic><topic>Dopamine D2 receptors</topic><topic>Dopamine Uptake Inhibitors - pharmacology</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical colleges</topic><topic>Memory, Short-Term - drug effects</topic><topic>Memory, Short-Term - physiology</topic><topic>Mental disorders</topic><topic>Middle Aged</topic><topic>Neostriatum</topic><topic>Neurosciences</topic><topic>Original Investigation</topic><topic>Personality</topic><topic>Personality disorders</topic><topic>PET imaging</topic><topic>Pharmacology/Toxicology</topic><topic>Phenols</topic><topic>Positron emission tomography</topic><topic>Positron-Emission Tomography - methods</topic><topic>Psychiatry</topic><topic>Raclopride</topic><topic>Receptors, Dopamine D2 - metabolism</topic><topic>Schizophrenia</topic><topic>Schizotypal personality disorder</topic><topic>Schizotypal Personality Disorder - diagnostic imaging</topic><topic>Schizotypal Personality Disorder - metabolism</topic><topic>Schizotypal Personality Disorder - psychology</topic><topic>Short term memory</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thompson, Judy L.</creatorcontrib><creatorcontrib>Rosell, Daniel R.</creatorcontrib><creatorcontrib>Slifstein, Mark</creatorcontrib><creatorcontrib>Xu, Xiaoyan</creatorcontrib><creatorcontrib>Rothstein, Ethan G.</creatorcontrib><creatorcontrib>Modiano, Yosefa A.</creatorcontrib><creatorcontrib>Kegeles, Lawrence S.</creatorcontrib><creatorcontrib>Koenigsberg, Harold W.</creatorcontrib><creatorcontrib>New, Antonia S.</creatorcontrib><creatorcontrib>Hazlett, Erin A.</creatorcontrib><creatorcontrib>McClure, Margaret M.</creatorcontrib><creatorcontrib>Perez-Rodriguez, M. Mercedes</creatorcontrib><creatorcontrib>Siever, Larry J.</creatorcontrib><creatorcontrib>Abi-Dargham, Anissa</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Psychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thompson, Judy L.</au><au>Rosell, Daniel R.</au><au>Slifstein, Mark</au><au>Xu, Xiaoyan</au><au>Rothstein, Ethan G.</au><au>Modiano, Yosefa A.</au><au>Kegeles, Lawrence S.</au><au>Koenigsberg, Harold W.</au><au>New, Antonia S.</au><au>Hazlett, Erin A.</au><au>McClure, Margaret M.</au><au>Perez-Rodriguez, M. Mercedes</au><au>Siever, Larry J.</au><au>Abi-Dargham, Anissa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Amphetamine-induced striatal dopamine release in schizotypal personality disorder</atitle><jtitle>Psychopharmacology</jtitle><stitle>Psychopharmacology</stitle><addtitle>Psychopharmacology (Berl)</addtitle><date>2020-09-01</date><risdate>2020</risdate><volume>237</volume><issue>9</issue><spage>2649</spage><epage>2659</epage><pages>2649-2659</pages><issn>0033-3158</issn><eissn>1432-2072</eissn><abstract>Rationale
Previous research has suggested that schizotypal personality disorder (SPD), a condition that shares clinical and cognitive features with schizophrenia, may be associated with elevated striatal dopamine functioning; however, there are no published studies of dopamine release within subregions of the striatum in SPD.
Objectives
To characterize dopamine release capacity in striatal subregions and its relation to clinical and cognitive features in SPD.
Methods
We used positron emission tomography with [
11
C]raclopride and an amphetamine challenge to measure dopamine D2-receptor availability (binding potential, BP
ND
), and its percent change post-amphetamine (∆BP
ND
) to index amphetamine-induced dopamine release, in subregions of the striatum in 16 SPD and 16 healthy control participants. SPD participants were evaluated with measures of schizotypal symptom severity and working memory.
Results
There were no significant group differences in BP
ND
or ∆BP
ND
in any striatal subregion or whole striatum. Among SPD participants, cognitive-perceptual symptoms were associated at trend level with ∆BP
ND
in the ventral striatum, and disorganized symptoms were significantly negatively related to ∆BP
ND
in several striatal subregions.
Conclusions
In contrast to previous findings, SPD was not associated with elevated striatal dopamine release. However, in SPD, there was a moderate positive association between ventral striatal dopamine release and severity of cognitive-perceptual symptoms, and negative associations between striatal dopamine release and severity of disorganized symptoms. Future larger scale investigations that allow for the separate examination of subgroups of participants based on clinical presentation will be valuable in further elucidating striatal DA functioning in SPD.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>32572588</pmid><doi>10.1007/s00213-020-05561-5</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-8964-4934</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0033-3158 |
ispartof | Psychopharmacology, 2020-09, Vol.237 (9), p.2649-2659 |
issn | 0033-3158 1432-2072 |
language | eng |
recordid | cdi_proquest_miscellaneous_2416272826 |
source | MEDLINE; SpringerLink Journals |
subjects | Adolescent Adult Amphetamine - pharmacology Amphetamines Biomedical and Life Sciences Biomedicine Brain research Cognitive ability Corpus Striatum - diagnostic imaging Corpus Striatum - drug effects Corpus Striatum - metabolism Dopamine Dopamine - metabolism Dopamine D2 receptors Dopamine Uptake Inhibitors - pharmacology Female Humans Male Medical colleges Memory, Short-Term - drug effects Memory, Short-Term - physiology Mental disorders Middle Aged Neostriatum Neurosciences Original Investigation Personality Personality disorders PET imaging Pharmacology/Toxicology Phenols Positron emission tomography Positron-Emission Tomography - methods Psychiatry Raclopride Receptors, Dopamine D2 - metabolism Schizophrenia Schizotypal personality disorder Schizotypal Personality Disorder - diagnostic imaging Schizotypal Personality Disorder - metabolism Schizotypal Personality Disorder - psychology Short term memory Young Adult |
title | Amphetamine-induced striatal dopamine release in schizotypal personality disorder |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-16T02%3A58%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Amphetamine-induced%20striatal%20dopamine%20release%20in%20schizotypal%20personality%20disorder&rft.jtitle=Psychopharmacology&rft.au=Thompson,%20Judy%20L.&rft.date=2020-09-01&rft.volume=237&rft.issue=9&rft.spage=2649&rft.epage=2659&rft.pages=2649-2659&rft.issn=0033-3158&rft.eissn=1432-2072&rft_id=info:doi/10.1007/s00213-020-05561-5&rft_dat=%3Cgale_proqu%3EA635911686%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2564698364&rft_id=info:pmid/32572588&rft_galeid=A635911686&rfr_iscdi=true |